These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37771101)

  • 1. Authors response to Management of dialysis patients with hepatitis C virus in the era of direct-acting antiviral therapy.
    Toyoda H; Kikuchi K
    Ther Apher Dial; 2024 Feb; 28(1):160-161. PubMed ID: 37771101
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of dialysis patients with hepatitis C virus in the era of direct-acting antiviral therapy.
    Jadoul M; Labriola L
    Ther Apher Dial; 2024 Feb; 28(1):158-159. PubMed ID: 37667594
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of dialysis patients with hepatitis C virus in the era of direct-acting antiviral therapy.
    Toyoda H; Kikuchi K
    Ther Apher Dial; 2023 Oct; 27(5):831-838. PubMed ID: 37217295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
    García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
    Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-drug interactions with direct-acting antivirals - less is more.
    Wong GL
    Clin Mol Hepatol; 2021 Jan; 27(1):81-82. PubMed ID: 33317241
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effectiveness and safety of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection].
    Yang J; Rao HY
    Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):175-178. PubMed ID: 29804389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Impact of Donor Hepatitis C Virus on Kidney Transplant Outcomes for Hepatitis C-Positive Recipients in the Direct-Acting Antiviral Era: Time to Revise the Kidney Donor Risk Index?
    Goldfarb DA
    J Urol; 2020 Dec; 204(6):1369. PubMed ID: 32955983
    [No Abstract]   [Full Text] [Related]  

  • 8. Five-Year Allograft Survival for Recipients of Kidney Transplants From Hepatitis C Virus Infected vs Uninfected Deceased Donors in the Direct-Acting Antiviral Therapy Era.
    Schaubel DE; Tran AH; Abt PL; Potluri VS; Goldberg DS; Reese PP
    JAMA; 2022 Sep; 328(11):1102-1104. PubMed ID: 35994263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evolution of clinical outcomes following hepatitis C virus clearance].
    Yang J; Rao HY
    Zhonghua Gan Zang Bing Za Zhi; 2022 Nov; 30(11):1137-1143. PubMed ID: 36891687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current management of hepatitis C].
    Lange CM
    Med Monatsschr Pharm; 2015 Sep; 38(9):337-44; quiz 345-6. PubMed ID: 26731851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late presentation of chronic hepatitis C patients in the era of direct-acting antivirals-Data from the German Hepatitis C-Registry.
    Bischoff J; Mauss S; Lutz T; Cordes C; Klausen G; Scholten S; Hillenbrand H; Cornberg M; Baumgarten A; Rockstroh JK;
    J Viral Hepat; 2021 Nov; 28(11):1660-1664. PubMed ID: 34289197
    [No Abstract]   [Full Text] [Related]  

  • 12. Direct-acting antiviral treatments in Australia for children with chronic hepatitis C virus infection.
    Eldredge JA; Stormon MO; Clark JE; Nightingale S; McMullan B; Andersen B; Travers C; Hardikar W
    Med J Aust; 2023 Mar; 218(5):229-230. PubMed ID: 36794442
    [No Abstract]   [Full Text] [Related]  

  • 13. Behind the Decrease of Liver Stiffness After Successful Hepatitis C Virus Eradication with Direct-Acting Antiviral Agents.
    Giuffrè M; Masutti F; Maria Crosato I; Luzzati R; Saveria Crocè L
    Turk J Gastroenterol; 2022 Feb; 33(2):169-170. PubMed ID: 35238783
    [No Abstract]   [Full Text] [Related]  

  • 14. Hepatitis C virus viral load distribution in the era of extended access to direct acting antivirals treatment: a real-life single center study.
    Basso M; Zago D; Pozzetto I; Parisi SG
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e1076-e1077. PubMed ID: 35048665
    [No Abstract]   [Full Text] [Related]  

  • 15. State Medicaid Restrictions for Direct-Acting Antiviral Therapy Do Not Impact Posttransplant Outcomes of Recipients of Hepatitis C Virus-Viremic Livers.
    Narasimman M; Goldberg DS
    Liver Transpl; 2021 Jan; 27(1):140-143. PubMed ID: 32979030
    [No Abstract]   [Full Text] [Related]  

  • 16. Creating an environment for equitable access to direct-acting antiviral therapy for people who inject drugs with hepatitis C.
    Dore GJ; Valerio H; Grebely J
    Liver Int; 2020 Oct; 40(10):2353-2355. PubMed ID: 33021345
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapeutic update in hepatitis C].
    Devesa MJ; Cuenca F; Izquierdo S; Sánchez-Pobre P; Ladero JM; López-Alonso G; Díaz-Rubio M; Rey E
    Rev Esp Quimioter; 2015 Sep; 28 Suppl 1():48-51. PubMed ID: 26365735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case report about curing chronic hepatitis C in children by direct-acting antiviral drugs].
    Chen N; Zhou Q; Cai LB
    Zhonghua Gan Zang Bing Za Zhi; 2021 Dec; 29(12):1196-1197. PubMed ID: 35045637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antiviral therapy of chronic hepatitis C: 30 years success story].
    Abdurakhmanov DT; Rozina TP; Nikulkina EN; Burnevich EZ; Tanashuk EL; Severov MV; Filatova AL; Milovanova SY; Karpov VV; Moiseev SV
    Ter Arkh; 2019 Nov; 91(11):110-115. PubMed ID: 32598621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. About the absolute need to keep active research on the efficacy of direct-acting antiviral drugs against the hepatitis C virus.
    Pawlotsky JM
    J Hepatol; 2020 Oct; 73(4):752-754. PubMed ID: 32732060
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.